Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
triptorelin
Description:
Triptorelin is a synthetic gonadotropin-releasing hormone agonist used in medicine to suppress reproductive hormone production.
Related topics:
Hypothalamic control of reproductive hormones (15%),
Reproductive Biology and Fertility (13%),
Prostate Cancer Treatment and Research (9%)
Wikidata ID:
wiki/Q1992452
OpenAlex ID:
keywords/triptorelin
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
2014
·
Olivia Pagani
, Meredith M. Regan
, et al.
·
New England Journal of Medicine
·
762
PDF
Effect of the Gonadotropin-Releasing Hormone Analogue Triptorelin on the Occurrence of Chemotherapy-Induced Early Menopause in Premenopausal Women With Breast Cancer: A Randomized Trial
2011
·
Lucia Del Mastro
, Luca Boni
, et al.
·
JAMA
·
362
Endocrine Profiles after Triggering of Final Oocyte Maturation with GnRH Agonist after Cotreatment with the GnRH Antagonist Ganirelix during Ovarian Hyperstimulation for in Vitro Fertilization
2002
·
B. C. Fauser
, D. de Jong
, et al.
·
The Journal of Clinical Endocrinology & Metabolism
·
349
Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial
2020
·
Paul Sargos
, Sylvie Chabaud
, et al.
·
The Lancet Oncology
·
345
PDF
GnRH antagonist in assisted reproduction: a Cochrane review
2002
·
H. Al-Inany
, Mohamed Aboulghar
·
Human Reproduction
·
344
Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials
2022
·
Rosie Bradley
, Jeremy Braybrooke
, et al.
·
The Lancet Oncology
·
326
PDF
A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists
2005
·
E.M. Kolibianakis
, A. Schultze-Mosgau
, et al.
·
Human Reproduction
·
320
Nonsupplemented Luteal Phase Characteristics after the Administration of Recombinant Human Chorionic Gonadotropin, Recombinant Luteinizing Hormone, or Gonadotropin-Releasing Hormone (GnRH) Agonist to Induce Final Oocyte Maturation inin VitroFertilization Patients after Ovarian Stimulation with Recombinant Follicle-Stimulating Hormone and GnRH Antagonist Cotreatment
2003
·
Nicole G. M. Beckers
, Nicholas S. Macklon
, et al.
·
The Journal of Clinical Endocrinology & Metabolism
·
308
Bone Mineral Density in Men Treated With Synthetic Gonadotropin-releasing Hormone Agonists for Prostatic Carcinoma
1999
·
J.F. MAILLEFERT
, J. SIBILIA
, et al.
·
The Journal of Urology
·
302
Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin)
2000
·
François Olivennes
, Joëlle Belaisch-Allart
, et al.
·
Fertility and Sterility
·
258
PDF
Long-Term Outcome after Depot Gonadotropin-Releasing Hormone Agonist Treatment of Central Precocious Puberty: Final Height, Body Proportions, Body Composition, Bone Mineral Density, and Reproductive Function
1999
·
Sabine Heger
, Carl-Joachim Partsch
, et al.
·
The Journal of Clinical Endocrinology & Metabolism
·
255
No Evidence for the Benefit of Gonadotropin-Releasing Hormone Agonist in Preserving Ovarian Function and Fertility in Lymphoma Survivors Treated With Chemotherapy: Final Long-Term Report of a Prospective Randomized Trial
2016
·
Isabelle Demeestere
, Pauline Brice
, et al.
·
Journal of Clinical Oncology
·
250
Randomized Trial Using Gonadotropin-Releasing Hormone Agonist Triptorelin for the Preservation of Ovarian Function During (Neo)Adjuvant Chemotherapy for Breast Cancer
2012
·
Pamela N. Munster
, Amy P. Moore
, et al.
·
Journal of Clinical Oncology
·
246
Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation
2001
·
The European Middle East Orgalutran® Study Group
·
Human Reproduction
·
241
Treatment of Men with Paraphilia with a Long-Acting Analogue of Gonadotropin-Releasing Hormone
1998
·
Ariel Rösler
, Eliezer Witztum
·
New England Journal of Medicine
·
217
Clinical Management of Youth with Gender Dysphoria in Vancouver
2013
·
Karine Khatchadourian
, Shazhan Amed
, et al.
·
The Journal of Pediatrics
·
207
High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines
1993
·
G Emons
, B Schröder
, et al.
·
The Journal of Clinical Endocrinology & Metabolism
·
207
Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival: A Randomized Clinical Trial
2015
·
Matteo Lambertini
, Luca Boni
, et al.
·
JAMA
·
205
Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: Short communication
2000
·
J. Itskovitz-Eldor
, S. Kol
, et al.
·
Human Reproduction
·
200
Effect of pubertal suppression and cross-sex hormone therapy on bone turnover markers and bone mineral apparent density (BMAD) in transgender adolescents
2016
·
Mariska C. Vlot
, Daniel T. Klink
, et al.
·
Bone
·
189
Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a “freeze-all” strategy: a prospective multicentric study
2011
·
Georg Griesinger
, Laura Schultz
, et al.
·
Fertility and Sterility
·
188
PDF
Final Height after Long-Term Treatment with Triptorelin Slow Release for Central Precocious Puberty: Importance of Statural Growth after Interruption of Treatment
1999
·
Jean-Claude Carel
, Marc Roger
, et al.
·
The Journal of Clinical Endocrinology & Metabolism
·
184
Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials
2015
·
Jürg Bernhard
, Weixiu Luo
, et al.
·
The Lancet Oncology
·
182
Decreased bone density in elderly men treated with the gonadotropin- releasing hormone agonist decapeptyl (D-Trp6-GnRH)
1993
·
D Goldray
, Y Weisman
, et al.
·
The Journal of Clinical Endocrinology & Metabolism
·
176
Dienogest in the treatment of endometriosis: systematic review
2015
·
Marina de Paula Andres
, Livia Alves Lopes
, et al.
·
Archives of Gynecology and Obstetrics
·
175
Show more works
View as search
Works count:
1,949
Citation count:
29,830
Year
Topic
Type